Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 77 companies hit new 52-week highs.
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication
The FDA has approved a second indication for GlaxoSmithKline plc’s (NYSE:GSK) Jemperli (dostarlimab-gxly). The approval comes for adult patients with mismatch repair…
AnaptysBioFDA Grants Accelerated Approval Of GSK’s JEMPERLI, Which Was Generated By AnaptysBio; Co. Has Earned $20M Milestone Payment As A Result
AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 55 companies set new 52-week highs.
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)
Analyzing GlaxoSmithKline’s Unusual Options Activity
GlaxoSmithKline (NYSE:GSK) shares experienced unusual options activity on Friday. The stock price moved up to $41.88 following the option alert.
Do mRNA COVID-19 Vaccines Cause Skin Or Kidney Disorders? EMA Investigates Possible Links
The European Medicines Agency is investing a possible link between mRNA vaccines and erythema multiforme or two kidney disorders by…